Osteoarthritis is a degenerative disease that leads to pain and deformity of the joints. Factors such as aging and trauma may contribute to injury and loss of cartilage, however the underlying biological mechanisms that cause osteoarthritis are still unknown.

The APPROACH consortium brings together a highly qualified and multidisciplinary group of stakeholders that will set up – for the first time – a broad database of different OA patients as well as a longitudinal cohort based on innovative stratification methods that identifies different osteoarthritis phenotypes. This will allow for the development of guidelines for differentially diagnosing the right patient for the right treatment.

The APPROACH project is funded by the European Innovative Medicines Initiative (IMI).

Facts & Figures


25 partners throughout Europe and one partner from the United States


€ 17.5 Million

Project period

5.5 years

Start date

1st of June 2015

Principal Investigators

Jonathan Larkin (GSK, coordinator)
Harrie Weinans (UMC Utrecht, managing entity)